ZP2 (NM_003460) Human Tagged ORF Clone Lentiviral Particle
CAT#: RC219115L3V
- LentiORF®
Lenti ORF particles, ZP2 (Myc-DDK tagged) - Human zona pellucida glycoprotein 2 (sperm receptor) (ZP2), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 13,965.00
货期*
详询
规格
Product images
经常一起买 (3)
Specifications
Product Data | |
Product Name | ZP2 (NM_003460) Human Tagged ORF Clone Lentiviral Particle |
Synonyms | OOMD6; Zp-2; ZPA |
Vector | pLenti-C-Myc-DDK-P2A-Puro |
ACCN | NM_003460 |
ORF Size | 2235 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(RC219115).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_003460.1 |
RefSeq Size | 2266 bp |
RefSeq ORF | 2238 bp |
Locus ID | 7783 |
Domains | zona_pellucida |
Protein Families | Secreted Protein, Transmembrane |
MW | 82.4 kDa |
Gene Summary | The zona pellucida is an extracellular matrix that surrounds the oocyte and early embryo. It is composed of three glycoproteins with various functions during fertilization and preimplantation development. The glycosylated mature peptide is one of the structural components of the zona pellucida and functions in secondary binding and penetration of acrosome-reacted spermatozoa. Female mice lacking this gene do not form a stable zona matrix and are sterile. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
You may also need
Customer
Reviews
Loading...